Progression-free (dashed line) and overall survival (solid line) with... | Download Scientific Diagram
EHA Library - The official digital education library of European Hematology Association (EHA)
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone - ScienceDirect
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse | Leukemia
FDA OK's New Triplet Tx for Revlimid-Refractory Multiple Myeloma | MedPage Today
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial - The Lancet Haematology
Progression-free survival with elotuzumab/pomalidomide/dexamethasone... | Download Scientific Diagram
Pomalidomide, Dexamethasone, & Elotuzumab Combo Trial
EMN 29 - Seli-Pom-Dex Vs Elo-Pom-Dex - Multiple Myeloma Clinical Trials
Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma | Cancer Chemotherapy and Pharmacology
FDA
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials | Haematologica
Clinical Trial: For Patients Resistant to Lenalidomide, the Antibody Elotuzumab With the Newer Pomalidomide and Dex for Relapsed/Refractory Myeloma - HealthTree for Myeloma
Elotuzumab Plus Pomalidomide and Dexamethasone for R/R Multiple Myeloma - Cancer Therapy Advisor
Combination Therapies - POMALYST® (pomalidomide)
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma | NEJM
When and How to Treat Relapsed Multiple Myeloma | American Society of Clinical Oncology Educational Book
Elotuzumab Plus Pomalidomide and Dexamethasone for Multiple Myeloma - YouTube
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma | NEJM
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma | NEJM
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study | Blood Cancer Journal
Multiple Myeloma with a Special Focus on Precision Medicine | Published in healthbook TIMES Oncology Hematology
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial | Journal of Clinical Oncology
